It is time to review concepts on renal involvement in leprosy: pre- and post-treatment evaluation of 189 patients

Figures & data

Table 1. Clinical and laboratory data of 189 patients with leprosy.

	N	Mean	SD	Reference range
Age (years)	189	44.06	16.02
Time since onset of symptoms and/or signs (months)	176	29.05	56.25
Serum urea (mg/dL)	187	28.61	9.17
Serum creatinine (mg/dL)	189	1.20	0.30
MDRD (mL/min)	189	62.58	15.90
Cockcroft–Gault (mL/min)	183	77.42	25.60
CPK (UI/L)	189	79.05	68.07	25–190
Glucose (mg/dL)	188	86.22	13.81	<110
Serum albumin (g/dL)	188	4.35	0.45	3–8
Serum globulin (g/dL)	188	2.95	0.67	2.30–3.50
Urinalysis
pH	189	5.72	0.87	5.0–9.0
Leukocytes (per mL)	189	6767.1	25 732	<9.000
Erythrocytes (per mL)	189	5746	19 111	<6.000
Protein (mg/dL)	189	4.77	7.14	<30
Microalbuminuria (mg/L)	188	10.55	27.25	20–200
urRBP (mg/L)	188	0.11	0.18	<0.40

Notes: MDRD, Modification of Diet in Renal Disease; urRBP, urinary retinol binding protein. Reference values for laboratory tests were those previously established for normal controls in our institution.

Table 2. The distribution of the different forms of leprosy according to the Ridley–Jopling scale.

Leprosy forms	N	Frequency (%)
Polar lepromatous (LL)	26	13.76
Borderline-lepromatous (BL)	33	17.46
Borderline-borderline (BB)	33	17.46
Borderline-tuberculoid (BT)	81	42.86
Polar tuberculoid (TT)	16	8.47
Total	189	100

Figure 1. The distribution of serum creatinine in 18 patients with erythema nodosum leprosum (ENL) before MDT and 3 and 8 months after the initiation of specific treatment (p = 0.039).

Figure 2. The distribution of serum creatinine (Screat) in patients with leprosy before MDT and 3 and 8 months after the initiation of specific treatment (p = 0.140).